The p-tau181 variant is the most studied p-tau biomarker and is today, together with total tau and amyloid-beta (Aβ) 42, used in clinical practice as a biomarker to detect AD pathology in patients with cognitive symptoms [9]. Here, MAPT is linked to Alzheimer disease.